‘Brutal disaster.’ Allergan’s would-be antidepressant fails patients in four studies
In 2015, Allergan spent $560 million on a small biotechnology company that had what appeared to be an important new treatment for depression. Now it looks like a "brutal disaster."
In 2015, Allergan spent $560 million on Naurex, a small biotechnology company that had what appeared to be an important new treatment for depression. Brent Saunders, Allergan’s CEO, called the deal “a compelling and exciting investment,” and said it could help in the most severe, treatment-resistant
